Foamix (FOMX) Announces Statistically Significant Top-Line Data from FDX104 Phase 2
Tweet Send to a Friend
Foamix (NASDAQ: FOMX) announced positive top-line results from its Phase 2 clinical study of FDX104 (a topical foam containing 4 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
